Zevalin ibritumomab tiuxetan: Preliminary Phase II data

Preliminary data from a single-arm, European Phase II trial in 60 treatment-naïve patients with follicular NHL showed that a single dose of IV Zevalin produced a 1-year ORR of 84%, with complete and partial response rates of 53% and 31%, respectively. Data were presented at the American Society of Hematology meeting in Orlando. ...